Form 4: Strata Medical Co-CEO Buys Shares, Disgorges Profits
Insider Trading Report
William A. Heyburn, Co-CEO and CFO of Strata Critical Medical, Inc., purchased 17,000 shares of Class A common stock but subsequently disgorged short-swing profits to the Issuer.
Summary
- William A. Heyburn, Co-CEO and CFO of Strata Critical Medical, Inc. (SRTA), purchased 17,000 shares of Class A common stock.
- The transaction occurred on December 9, 2025, at a weighted average price of $4.4732 per share, with prices ranging from $4.45 to $4.48.
- Following this transaction, Heyburn beneficially owns 1,403,436 shares directly.
- Heyburn realized short-swing profits under Section 16(b) of the Exchange Act from these transactions.
- On December 10, 2025, Heyburn disgorged these short-swing profits to Strata Critical Medical, Inc.
Sentiment
Score: 4
Explanation: While an insider purchase can be seen as positive, the immediate realization and disgorgement of short-swing profits due to a Section 16(b) violation introduces a significant negative compliance and reputational element, outweighing the positive signal of the purchase itself.
Positives
- The Co-CEO and CFO, William A. Heyburn, purchased 17,000 shares of Class A common stock, which could be interpreted as a signal of confidence in the company's future prospects.
Negatives
- William A. Heyburn realized short-swing profits under Section 16(b) of the Exchange Act, indicating a compliance violation.
- Heyburn was required to disgorge the short-swing profits to the Issuer on December 10, 2025, due to the Section 16(b) violation.
Risks
- Risk of non-compliance with Section 16(b) of the Securities Exchange Act of 1934, which prohibits insiders from profiting from purchases and sales of company stock within a six-month period.
- Potential reputational risk for the Co-CEO and CFO, and by extension the company, due to the Section 16(b) violation.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
This filing is a standard insider transaction report and does not provide information relevant to broader industry trends or competitor analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compliance Issue | A Section 16(b) short-swing profit violation occurred, requiring the Co-CEO and CFO to disgorge profits to the Issuer. This highlights a lapse in insider trading compliance. | 12/10/2025 | Indicates a need for stricter adherence to insider trading policies and potentially enhanced training for executives on Section 16 rules to prevent future occurrences. |
Stakeholder Impact
- Shareholders: Potential concern regarding executive compliance with insider trading rules, though the profits were disgorged to the company.
- Management: Reputational impact on the Co-CEO and CFO, and potentially on the company's executive team regarding compliance oversight.
Key Dates
| Date | Description |
|---|---|
| 12/09/2025 | Date of transaction where William A. Heyburn acquired 17,000 shares of Class A common stock. |
| 12/10/2025 | Date when William A. Heyburn disgorged Section 16(b) short-swing profits to Strata Critical Medical, Inc. |
Keywords
Strata Critical Medical, SRTA, Insider Trading, Form 4, Stock Purchase, Section 16(b), Short-Swing Profits, William A. Heyburn, Co-CEO, CFO, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.